Oral Immunotherapy and Anti-IgE Antibody-Adjunctive Treatment for Food Allergy

Immunology and Allergy Clinics of North America

Volumn 32, Issue 1, 2012, Pages 111-133

  Nadeau, Kari C ^a   Kohli, Arunima ^a   Iyengar, Shuba ^b   DeKruyff, Rosemarie H ^c   Umetsu, Dale T ^c  

^a STANFORD UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Anti IgE antibody omalizumab; Desensitization; Food allergy; Immunotherapy

Indexed keywords

EGG PROTEIN; FOOD ALLERGEN; IMMUNOGLOBULIN E; MILK PROTEIN; OMALIZUMAB; PLACEBO; TALIZUMAB;

ABDOMINAL PAIN; ALLERGIC REACTION; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DESENSITIZATION; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; EGG ALLERGY; FOOD ALLERGY; HUMAN; INTERMETHOD COMPARISON; MILK ALLERGY; NAUSEA; ORAL IMMUNOTHERAPY; PEANUT ALLERGY; PRIORITY JOURNAL; PRURITUS; RAGWEED; REVIEW; RHINITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; WHEEZING;

ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; FOOD; FOOD HYPERSENSITIVITY; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INFANT; MIDDLE AGED; YOUNG ADULT;

EID: 84855822855     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2011.11.004     Document Type: Review

References (58)

1. Land M., Kim E.H., Burks W. Oral desensitization for food hypersensitivity. Immunol Allergy Clin North Am 2011, 31:367-376.
2. Bock S.A., Sampson H.A. Food allergy in infancy. Pediatr Clin North Am 1994, 41:1047-1067.
3. Chafen J.J., Newberry S.J., Riedl M.A., et al. Diagnosing and managing common food allergies: a systematic review. JAMA 2010, 303:1848-1856.
4. Mills C, van Ree R, Breteneder H. Food allergy and intolerance in Europe-future directions within the ERA. Allergen Bureau Web site. Available at: Accessed September 19 2011. http://www.allergenbureau.net/downloads/projects-and-resources/Food_Allergy_in_Europe.pdf.
5. Food allergy and food intolerance. European Food Information Council Web site. Available at: Accessed September 19 2011. http://www.eufic.org/article/en/expid/basics-food-allergy-intolerance/.
6. Shek L.P., Lee B.W. Food allergy in Asia. Curr Opin Allergy Clin Immunol 2006, 6(3):197-201.
7. Jones S.M., Pons L., Roberts J.L., et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. JAllergy Clin Immunol 2009, 124(2):292-300. 300.e1-97.
8. Sampson H.A., Rosen J.P., Selcow J.E., et al. Intradermal skin tests in the diagnostic evaluation of food allergy. JAllergy Clin Immunol 1996, 98:714-715.
9. Sampson H.A., Munoz-Furlong A., Campbell R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006, 47:373-380.
10. Nowak-Wegrzyn A., Muraro A. Food allergy therapy: is a cure within reach?. Pediatr Clin North Am 2011, 58:511-530.
11. Scurlock A.M., Burks A.W., Jones S.M. Oral immunotherapy for food allergy. Curr Allergy Asthma Rep 2009, 9:186-193.
12. Nowak-Wegrzyn A., Sampson H.A. Future therapies for food allergies. JAllergy Clin Immunol 2011, 127(3):558-573.
13. Scurlock A.M., Vickery B.P., Hourihane J.O., et al. Pediatric food allergy and mucosal tolerance. Mucosal Immunol 2010, 3(4):345-354.
14. Patriarca C., Romano A., Venuti A., et al. Oral specific hyposensitization in the management of patients allergic to food. Allergol Immunopathol (Madr) 1984, 12(4):275-281.
15. Bauer A., Ekanayake Mudiyanselage S., Wigger-Alberti W., et al. Oral rush desensitization to milk. Allergy 1999, 54(8):894-895.
16. Patriarca G., Nucera E., Roncallo C., et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther 2003, 17:459-465.
17. Meglio P., Bartone E., Plantamura M., et al. Aprotocol for oral desensitization in children with IgE-mediated cow's milk allergy. Allergy 2004, 59:980-987.
18. Buchanan A.D., Green T.D., Jones S.M., et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. JAllergy Clin Immunol 2007, 119(1):199-205.
19. Staden U., Rolinck-Werninghaus C., Brewe F., et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 2007, 62:1261-1269.
20. Longo G., Barbi E., Berti I., et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. JAllergy Clin Immunol 2008, 121(2):343-347.
21. Skripak J.M., Nash S.D., Rowley H., et al. Arandomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. JAllergy Clin Immunol 2008, 122(6):1154-1160.
22. Clark A.T., Islam S., King Y., et al. Successful oral tolerance induction in severe peanut allergy. Allergy 2009, 64(8):1218-1220.
23. Blumchen K., Ulbricht H., Staden U., et al. Oral peanut immunotherapy in children with peanut anaphylaxis. JAllergy Clin Immunol 2010, 126(1). 83.e1-91.e1.
24. Varshney P., Jones S.M., Scurlock A.M., et al. Arandomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. JAllergy Clin Immunol 2011, 127(3):654-660.
25. Skripak J.M., Matsui E.C., Mudd K., et al. The natural history of IgE-mediated cow's milk allergy. JAllergy Clin Immunol 2007, 120(5):1172-1177.
26. Durham S.R., Walker S.M., Varga E.-M., et al. Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. NEngl J Med 1999, 341(7):468-475.
27. Sicherer S.H. Food allergy. Mt Sinai J Med 2011, 78(5):683-696.
28. Burks W., Ballmer-Weber B.K. Food allergy. Mol Nutr Food Res 2006, 50(7):595-603.
29. Pelaia G., Renda T., Romeo P., et al. Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther Adv Respir Dis 2008, 2(6):409-421.
30. Xolair: Omalizumab. United States Food and Drug Administration Web site. Available at: Accessed October 12, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103976s5102lbl.pdf.
31. Xolair (omalizumab). European Medicines Agency Web site. Available at: Accessed October 12, 2011. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/000606/human_med_001162.jsp%26mid=WC0b01ac058001d124%26jsenabled=true.
32. Humbert M., Beasley R., Ayres J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
33. Corren J., Casale T., Deniz Y., et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma- related emergency room visits and hospitalizations in patients with allergic asthma. JAllergy Clin Immunol 2003, 111:87-90.
34. Lanier B., Bridges T., Kulus M., et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. JAllergy Clin Immunol 2009, 124:1210-1216.
35. Rodrigo G.J., Neffen H., Castro-Rodriguez J.A. Efficacy and safety of subcutaneous omalizumab versus placebo as add on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011, 139(1):28-35.
36. Casale T.B., Condemi J., LaForce C., et al. Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001, 286:2956-2967.
37. Chervinsky P., Casale T., Townley R., et al. Omalizumab, an anti- IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003, 91:160-167.
38. Okubo K., Ogino S., Nagakura T., et al. Omalizumab is effective and safe in the treatment of Japanese cedar pollen- induced seasonal allergic rhinitis. Allergol Int 2006, 55:379-386.
39. Kuehr J., Brauburger J., Zielen S., et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in poly- sensitized children and adolescents with seasonal allergic rhinitis. JAllergy Clin Immunol 2002, 109(2):274-280.
40. Kopp M.V., Brauburger J., Riedinger F., et al. The effect of anti-IgE treatment on invitro leukotriene release in children with seasonal allergic rhinitis. JAllergy Clin Immunol 2002, 110:728-735.
41. Kopp M.V., Stenglein S., Kamin W., et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential invitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 2007, 18:523-527.
42. Leung D.Y., Sampson H.A., Yunginger J.W., et al. Effect of anti-IgE therapy in patients with peanut allergy. NEngl J Med 2008, 348(11):986-993.
43. Corren J., Shapiro G., Reimann J., et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. JAllergy Clin Immunol 2008, 121(2):506-511.
44. MacGlashan D.W., Bochner B.S., Adelman D.C., et al. Downregulation of FcεRI expression on human basophils during invivo treatment of atopic patients with anti-IgE antibody. JImmunol 1997, 158:1438-1445.
45. Stone K.D., Prussin C., Metalfe D.D. IgE, mast cells, basophils, and eosinophils. JAllergy Clin Immunol 2010, 125(2):S73-S80.
46. Belliveau P.P. Omalizumab: a monoclonal anti-IgE antibody. MedGenMed 2005, 7(1):27.
47. Noga O., Hanf G., Kunkel G. Immunological changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003, 131:46-52.
48. Djukanovic R., Wilson S.J., Kraft M. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004, 170(6):583-593.
49. Ong Y.E., Menzies-Gow A., Barkans J., et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. JAllergy Clin Immunol 2005, 116(3):558-564.
50. Lowe P.J., Tannenbaum S., Gautier A., et al. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009, 68(1):61-76.
51. Casale T.B., Busse W.W., Kline J.N., et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. JAllergy Clin Immunol 2006, 117(1):134-140.
52. Sampson H.A., Leung D.Y., Burks A.W., et al. Aphase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. JAllergy Clin Immunol 2011, 127(5). 1309.e1-10.e1.
53. Iyengar S.R., Hoyte E.G., Loza A., et al. Safety of omalizumab treatment in children (>4 years) with high serum IgE and severe atopic dermatitis and food allergy. JAllergy Clin Immunol 2008, 121(2):S1-S32.
54. Nadeau K.C., Schneider L.C., Hoyte L., et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. JAllergy Clin Immunol 2011, 127(6):1622-1624.
55. Available at: Accessed November 14, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00932282?term=burks%2C+peanut&rank=2.
56. Cross M.L., Gill H.S. Can immunoregulatory lactic acid bacteria be used as dietary supplements to limit allergies?. Int Arch Allergy Immunol 2001, 125(2):112-119.
57. Ridolo E., De Angelis G.L., Dall'Aglio P. Eosinophilic esophagitis after specific oral tolerance induction for egg protein. Ann Allergy Asthma Immunol 2011, 106(1):73-74.
58. Golden D.B. Insect sting allergy and venom immunotherapy: a model and a mystery. JAllergy Clin Immunol 2005, 115(3):439-447.